No black box warning on record for Mavyret

As of the latest FDA labeling reviewed, Mavyret (GLECAPREVIR AND PIBRENTASVIR) does not carry a black box warning. Standard warnings and precautions still apply — see the full Mavyret medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Risk of Hepatitis B Virus Reactivation: Test all patients for evidence of current or prior HBV infection before initiation of HCV treatment. Monitor HCV/HBV coinfected patients for HBV reactivation and hepatitis flare during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated. ( 5.1 ) Risk of Hepat

No black box warning on record for Mavyret

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Risk of Hepatitis B Virus Reactivation: Test all patients for evidence of current or prior HBV infection before initiation of HCV treatment. Monitor HCV/HBV coinfected patients for HBV reactivation and hepatitis flare during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated. ( 5.1 ) Risk of Hepat

Mavyret Black Box Warning

No black box warning on record for Mavyret

Other warnings & precautions

Mavyret Black Box Warning

No black box warning on record for Mavyret

Other warnings & precautions